VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety[1].
VQW-765 对重组表达的人 α7-nACh 受体的 pKD 值为 7.56[1]。
VQW-765 在 GH3-ha7-22 细胞中重组表达的人 α7-nACh 受体刺激后，显示出对钙瞬态的强大激动活性，pEC50 值为 7.41[1]。
VQW-765 (0.03 和 0.3 mg/kg；口服，一次) 增加小鼠的认知和学习、记忆表现[1]。
VQW-765 (1 mg/kg；口服，一次) 显示出抗焦虑作用，增加大鼠的社会探索时间，持续时间至少6小时[1]。
| Animal Model: | OF1/IC strain adult mice[1] |
| Dosage: | 0.03 and 0.3 mg/kg |
| Administration: | Oral administration; 0.03 and 0.3 mg/kg once |
| Result: | Increased the learning/memory performance with more time to scrutinize the novel partner than the familiar partner during the re-test trial at 24 h. Showed cognitive-enhancing effects in mice by the object recognition test (ORT). |
[1]. Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304.